Latest News for: dipraglurant

Edit

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with ...

Ottumwa Courier 17 Jun 2022
COVID-19 related challenges negatively impacted patient recruitment ... .
Edit

Addex Terminates Dipraglurant Phase 2B/3 Study In Patients With Dyskinesia Associated With Parkinson's Disease Due ...

MENA FN 17 Jun 2022
(MENAFN - GlobeNewsWire - Nasdaq) COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland , Ju ne 17 ... .
Edit

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate (Addex Therapeutics Ltd)

Public Technologies 17 Jun 2022
) Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate ... I'd like to emphasize that it was not dipraglurant related and we continue to believe in the potential of this compound as a treatment for PD-LID," said Tim Dyer, Chief Executive Officer of Addex.
Edit

Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate - Form 6-K (Addex Therapeutics Ltd)

Public Technologies 17 Jun 2022
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate ... I'd like to emphasize that it was not dipraglurant related and we continue to believe in the potential of this compound as a treatment for PD-LID," said Tim Dyer, Chief Executive Officer of Addex.
Edit

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Nasdaq Globe Newswire 27 May 2022
Ad Hoc Announcement Pursuant to Art. 53 LR ... .
Edit

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study (Addex Therapeutics Ltd)

Public Technologies 27 May 2022
ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives ... About Dipraglurant..
Edit

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study - Form 6-K (Addex Therapeutics Ltd)

Public Technologies 27 May 2022
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study ... Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM ... The primary objective of the study was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
Edit

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

MENA FN 13 Apr 2022
(MENAFN - GlobeNewsWire - Nasdaq) Top-line Data Schedule d to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland , April 1 3 , 202 2 - ... .
Edit

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study (Addex Therapeutics Ltd)

Public Technologies 13 Apr 2022
Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm ... The primary objective of the study is to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
Edit

Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study - Form 6-K (Addex Therapeutics Ltd)

Public Technologies 13 Apr 2022
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study ... Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm.
Edit

Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

Nasdaq Globe Newswire 29 Sep 2021
Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness ... .
Edit

Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm (Addex Therapeutics Ltd)

Public Technologies 29 Sep 2021
Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) to downregulate neurotransmission through allosteric modulation ... It is designed to assess the safety and tolerability of dipraglurant (50 and 100mg) as well as explore its effects on the ...
Edit

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson's Disease

MENA FN 29 Jun 2021
(MENAFN - GlobeNewsWire - Nasdaq)main-body-container" itemprop="articleBody"> Geneva, Switzerland , June 29 , 202 1 - Addex Therapeutics Ltd (SIX. ADXN, Nasdaq. ADXN), a ... .
Edit

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease

Nasdaq Globe Newswire 29 Jun 2021
... started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID).
Edit

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease (Addex Therapeutics Ltd)

Public Technologies 29 Jun 2021
ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID).

Article Search

tools

Most Viewed

Biden: ‘The pandemic is over’
The Hill
19 Sep 2022
U.S President Joe Biden travels in a convoy passing Buckingham Palace in London, England, Sunday, Sept. 18, 2022.
AP / Martin Meissner
Biden says US forces would defend Taiwan against ‘unprecedented attack’
Tacoma News Tribune
19 Sep 2022
A Taiwanese tank fires at targets during a military exercise in Hengchun, Pingtung county in southern Taiwan on Wednesday, Sept. 7, 2022
AP / Huizhong Wu
What happens if Putin goes nuclear in Ukraine? Biden has a choice to make
The Observer
18 Sep 2022
Ukrainian servicemen stand atop a destroyed Russian tank in a retaken area near the border with Russia in Kharkiv region, Ukraine, Saturday, Sept. 17, 2022.
AP / Leo Correa
Hurricane Fiona Slams Into Puerto Rico
The Maritime Executive
19 Sep 2022
A worker cuts an electricity pole that was downed by Hurricane Fiona as it blocks a road in Cayey, Puerto Rico, Sunday, Sept. 18, 2022
AP / Stephanie Rojas
Somali Militia Beheads Islamist Insurgents After Battle, Witnesses Say
Voa News
19 Sep 2022
FILE - In this Dec. 8, 2008 file photo, armed al-Shabab fighters on pickup trucks prepare to travel into the city, just outside Mogadishu, in Somalia.
AP / Farah Abdi Warsameh, File
Japan asks over 8M people to evacuate due to powerful Typhoon Nanmadol
Anadolu Agency
19 Sep 2022
A man struggles with his umbrella as he was visiting to pray at the famed Sensoji temple in Tokyo, Friday, Oct. 1, 2021
AP / Hiro Komae
Pelosi condemns Azerbaijan over Armenia attack
Federal News Radio
19 Sep 2022
Speaker of the House Nancy Pelosi of Calif., speaks during the unveiling ceremony of the official portrait of the late Congressman Elijah Cummings on Capitol Hill in Washington, Wednesday, Sept. 14, 2022.
AP / Jose Luis Magana
Denmark,Sweden,Norway and Others Multiple all Open and Free- Biggest Fraud in History the World,Bitchute
WorldNews.com
19 Sep 2022
2020 coronavirus pandemic in Denmark - The DFDS ferries Peals Seaways and Crown Seaways and at the terminal in Copenhagen seen from Marmormolen
Creative Commons / Leif Jørgensen
First public global database of fossil fuels launches
The Associated Press
19 Sep 2022
A pumpjack of Wintershall DEA extracting crude oil at an old oil field in Emlichheim, Germany, Friday, March 18, 2022.
AP / Martin Meissner
Zelensky promises no ‘lull’ in taking back Ukrainian towns
The Los Angeles Times
19 Sep 2022
A Ukrainian serviceman stands at the checkpoint near the recently retaken area of Izium, Ukraine, Thursday, Sept. 15, 2022
AP / Evgeniy Maloletka
Ukraine Alleges Torture at Village Near Russian Border
Voa News
19 Sep 2022
A member of the State Emergency Service of Ukraine enters in the basement of the train station fortified with sand bags that, according to Ukrainian authorities, was used as an interrogation room during the Russian occupation in the retaken village of Kozacha Lopan, Ukraine, Sunday, Sept. 18, 2022
AP / Leo Correa
Retired General Compares Trump's Ohio Rally to Hitler's 1936 Nazi Event
Newsweek
18 Sep 2022
Donald Trump speaking with supporters at a "Keep America Great" rally in Phoenix, Arizona, 19/02/2020
Creative Commons / Gage Skidmore
Study: Americans own more than 415 million firearms
The Epoch Times
18 Sep 2022
Pistol Titan caliber 45 blue gun, on display at a gun show. Taken on July 2017.
WN / RTayco
Clearview AI, Used by Police to Find Criminals, Now in Public Defenders’ Hands
New York Times
18 Sep 2022
Symposium Cisco Ecole Polytechnique 9-10 April 2018 Artificial Intelligence & Cybersecurity
Creative Commons / École polytechnique - J.Barande
Hungary Government Feels the Pinch as EU Moves to Freeze Funds
Balkan Insight
19 Sep 2022
Hungarian Prime Minister Viktor Orban speaks at the Conservative Political Action Conference (CPAC) in Dallas, Thursday, Aug. 4, 2022
AP / LM Otero
×
×
×
×